A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer

Abstract Background Triple-negative breast cancer (TNBC) remains an aggressive breast cancer subtype with limited treatment options. ENMD-2076 is a small-molecule inhibitor of Aurora and angiogenic kinases with proapoptotic and antiproliferative activity in preclinical models of TNBC. Methods This d...

Full description

Bibliographic Details
Main Authors: Jennifer R. Diamond, S. G. Eckhardt, Todd M. Pitts, Adrie van Bokhoven, Dara Aisner, Daniel L. Gustafson, Anna Capasso, Sharon Sams, Peter Kabos, Kathryn Zolman, Tiffany Colvin, Anthony D. Elias, Anna M. Storniolo, Bryan P. Schneider, Dexiang Gao, John J. Tentler, Virginia F. Borges, Kathy D. Miller
Format: Article
Language:English
Published: BMC 2018-08-01
Series:Breast Cancer Research
Subjects:
Breast cancer
ENMD-2076
Aurora kinase inhibitor
Triple negative
Online Access:http://link.springer.com/article/10.1186/s13058-018-1014-y

Internet

http://link.springer.com/article/10.1186/s13058-018-1014-y

Similar Items